INNOVA CAPTAB LIMITED
Plot No. 320, Industrial Area, Phase-1,
Panchkula, Pin-134113, Haryana, India.
Phone: +91-172-4194500

13th November, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex
Bandra (E), Mumbai – 400051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Intimation of investor presentation for the analysts/institutional Investor meeting to be held for financial results of the quarter and half year ended 30th September, 2026.

This is in continuation to our intimation dated 05th November, 2026 wherein we had informed regarding an earnings call scheduled with analysts/investors on Monday, 16th November, 2026 at 11:00 hours (IST) to discuss the unaudited financial results for the quarter and half year ended 30th September, 2026.

Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") as amended, please find enclosed herewith the investor presentation for the said earnings call.

This is for your information and record.

Thanking you,

Yours faithfully,
For and on behalf of Innova Captab Limited

NEEHARIKA SHUKLA
Digitally signed by NEEHARIKA SHUKLA
Date: 2026.11.13 20:40:05 +05'30'

Neeharika Shukla
Company Secretary and Compliance Officer

Encl.: A/a

GROWTH

BUILT ON CONSISTENCY

Investor Presentation – November 2026



Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Innova Captab Limited (the "Company"),** have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Company Overview



Leading Pharmaceutical Player with Comprehensive Business Model

Preferred CDMO partner for prominent pharmaceutical companies worldwide, with a strong direct presence across geographies through our branded generics business

350 +
CDMO Customers across the Globe

Presence across **60+** countries

Comprehensive portfolio of **4,200+** products

Serving some of the **prominent** Pharmaceutical companies globally

Strong network of **2,50,000+** touchpoints in India

Robust Financials
(FY26)

Revenues
₹ 1,630 Cr

EBITDA
₹ 250 Cr
(15.4%)

PAT
₹ 143 Cr
(8.8%)

ROCE
14.6%

Transforming Vision into Milestones of Growth

2006
Foundation
The journey commenced with the establishment of the first manufacturing facility in Baddi, Himachal Pradesh, marking our Company's entry into pharmaceutical manufacturing.

2010
Establishment of Cephalosporin Plant
A dedicated cephalosporin block was commissioned at the Baddi facility, enhancing manufacturing capabilities and product depth.

2013
International GMP Certification
Global quality credentials were strengthened with the receipt of GMP certification for cephalosporin products from the Ministry of Medical Services, Republic of Kenya.

2015
Establishment of Marketing Arm
Marketing and operational capabilities were expanded through the incorporation of Univentis Medicare Limited.

2017
Establishment of G Block
Initiated operations at the newly established G Block facility within the Baddi plant.

2021
Further Expansion
The capacity of the G Block was expanded to support growing demand and improve operational throughput.


2022
Strategic Expansion
Expansion plans were accelerated with the initiation of a manufacturing facility in Kathua, Jammu.

2023
Acquisition & IPO Milestones
Capabilities and product offerings were strengthened through the acquisition of Sharon, followed by the successful listing on stock exchanges.

2025
Commercialization of manufacturing facility in Kathua, Jammu
Commercial operations at our state-of-the-art manufacturing facility in Kathua, Jammu commenced in January 2025, marking a significant milestone in our capacity expansion journey.

2026
Global Certifications
Received Certificate of GMP Compliance by UK-MHRA for Cephalosporin, Baddi facility and received Certificate of GMP Compliance from PIC/S (SMDC, Ukraine) for Kathua, Jammu facility.

With State-of-the-Art Manufacturing Facilities



9

Manufacturing Blocks
3 Baddi |1 Dehradun |1 Taloja | 4 Jammu

New Greenfield

Multipurpose Facility
(4 manufacturing blocks) in Kathua, Jammu commercialized in Jan'25

Among the largest

Finished Tablet and Capsule Manufacturing Capacity in India

High FATR

Track record of operating at high Fixed Asset Turnover Ratio

Key Accreditations

MHRA

Health Canada Santé Canada

EUROPEAN UNION GMP

State Service of Ukraine on Medicines and Drugs Control


Food, Medicine and Healthcare Administration and Control Authority of Ethiopia

GOOD MANUFACTURING PRACTICE GMP CERTIFIED GOOD MANUFACTURING PRACTICE

Disclaimer: This map is a generalized illustration only for the ease of the reader to understand the locations, and it is not intended to be used for reference purposes. The representation of political boundaries and the names of geographical features/states do not necessarily reflect the actual position. Our Company or any of our Directors, officers or employees cannot be held responsible for any misuse or misinterpretation of any information or design thereof. Our Company does not warrant or represent any kind of connection with its accuracy or completeness.

Disciplined Capital Allocation Driving Sustainable Growth

(₹ in Crs)



Q2 & H1FY27
Performance Highlights



MD's Commentary

Innova Captab Limited delivered a strong performance in Q2FY27, with revenue growing 30.5% YoY to ₹ 496.3 crore, EBITDA increasing 29.2% to ₹ 72.4 crore and PAT growing 43.0% to ₹ 42.4 crore.

The performance underscores the continued strength of our diversified business model and disciplined execution across our business operations.


The company continued to witness healthy business momentum across its CDMO and Branded Generics businesses, supported by a diversified product portfolio and deeper customer engagement. Our focus on operational excellence, manufacturing efficiency and quality continues to strengthen our competitive positioning and enables us to meet the evolving requirements of domestic and international markets. We are unequivocally focused on continued Jammu ramp up alongside further strengthening of our manufacturing capabilities.

Going forward, the company remains committed to strengthen its CDMO positioning, expand its branded generics presence and to ramp up manufacturing capacities. We remain confident of sustaining long term growth and value for stakeholders through our strategic roadmap focusing on timely and disciplined capital allocation decisions.




Q2 & H1 FY27 Performance Highlights - Revenue

Revenue (₹ Crore)



Business Areas (₹ Crore)



- Revenue from Operations recorded robust growth of 30% YoY, reaching ₹496.3 crore in Q2 FY27. For H1 FY27, revenue grew 32% year-on-year to ₹967.2 crore, reflecting sustained business momentum.

- CDMO Services & Products revenue stood at ₹345.2 crore in Q2 FY27, registering a 30% YoY growth. For H1 FY27, revenue increased 31% to ₹673.9 crore, supported by continued client traction and healthy business momentum.

    - CDMO Services & Products remained the key growth engine, contributing approximately 70% of total revenue in both Q2 and H1 FY27, highlighting the strength of the Company's core business.

- Branded Generics revenue increased to ₹151.1 crore in Q2 FY27, registering a 32% YoY growth. For H1 FY27, revenue grew 35% to ₹293.3 crore, reflecting sustained growth across the portfolio.

    - Growth in Branded Generics was supported by expanding market reach, deeper penetration across existing markets and continued traction across the portfolio.

Q2 & H1 FY27 Performance Highlights - Profitability

EBITDA (₹ crore)

	Q2 FY26	Q2 FY27	H1 FY26	H1 FY27
Margin	14.7%	14.6%	15.4%	15.3%
EBITDA	56.1	72.4	112.6	147.5
		+29%		+31%

PAT (₹ crore)

	Q2 FY26	Q2 FY27	H1 FY26	H1 FY27
Margin	7.8%	8.5%	8.3%	8.9%
PAT	29.7	42.4	60.7	86.5
		+43%		+43%

- EBITDA grew by a robust 29% YoY to ₹72.4 crore in Q2 FY27, compared to ₹56.1 crore in Q2 FY26. For H1 FY27, EBITDA increased by 31% to ₹147.5 crore, compared to ₹112.6 crore in H1 FY26.
- EBITDA Margin stood at 14.6% in Q2 FY27 compared to 14.7% in Q2 FY26. For H1 FY27, EBITDA margin came in at 15.3% compared to 15.4% in H1 FY26
- Profit After Tax (PAT) registered strong growth of 43% YoY to ₹42.4 crore in Q2 FY27, compared to ₹29.7 crore in Q2 FY26. For H1 FY27, PAT also grew by 43% to ₹86.5 crore, compared to ₹60.7 crore in H1 FY26.
- PAT Margin improved to 8.5% in Q2 FY27 compared to 7.8% in Q2 FY26. For H1 FY27, PAT margin expanded to 8.9% from 8.3% in H1 FY26, reflecting an improvement of 60 bps.

Note: Margins are calculated on Revenue from operations

Consolidated Profit & Loss Statement

Profit and Loss (₹ crore)	Q2 FY27	Q2 FY26	YoY Growth	H1 FY27	H1 FY26	YoY Growth
Revenue from Operations	**496.3**	**380.4**	**30.5%**	**967.2**	**731.9**	**32.1%**
Other Income	2.5	4.2		4.5	8.7	
Total Income	**498.8**	**384.6**	**29.7%**	**971.6**	**740.6**	**31.2%**
Cost of Material Consumed	331.6	243.6		635.5	464.3	
Employee Cost	45.1	41.7		89.9	80.8	
Other Expenses	49.7	43.2		98.7	82.8	
EBITDA	**72.4**	**56.1**	**29.2%**	**147.5**	**112.6**	**31.0%**
EBITDA Margin	**14.6%**	**14.7%**		**15.3%**	**15.4%**	
Depreciation	11.8	11.3		23.5	22.4	
Finance Cost	4.3	5.5		8.7	8.4	
Profit before Tax	**56.3**	**39.2**		**115.3**	**81.9**	
Tax	13.9	9.6		28.7	21.2	
Profit After Tax	**42.4**	**29.7**	**43.0%**	**86.5**	**60.7**	**42.6%**
Profit After Tax Margin	**8.5%**	**7.8%**		**8.9%**	**8.3%**	
EPS (in ₹)	7.41	5.18		15.12	10.60	

Consolidated Balance Sheet

Assets (₹ crore)	Sept-26	Mar-26
Non - Current Assets	**884.6**	**914.9**
Property, plant and equipment	778.5	779.7
Right of use assets	43.3	43.7
Capital work-in-progress	9.3	15.5
Goodwill	16.7	16.7
Other intangible assets	1.6	1.5
Financial Assets		
Loans	0.5	0.4
Other financial assets	9.9	41.6
Deferred tax assets (net)	2.1	1.9
Other non-current assets	22.8	14.0
Current Assets	**1,109.4**	**923.0**
Inventories	316.9	283.3
Financial Assets		
Investments	82.9	41.3
Trade receivables	490.2	437.3
Cash and cash equivalents	14.9	3.2
Other bank balances	0.1	0.7
Loans	0.4	0.4
Other financial assets	134.4	86.9
Other current assets	69.7	69.9
Total Assets	**1,994.1**	**1,837.8**

Equity & Liabilities (₹ crore)	Sept-26	Mar-26
Total Equity	**1,167.6**	**1,081.5**
Share Capital	57.2	57.2
Other Equity	1110.3	1024.3
Non-Current Liabilities	**253.3**	**261.7**
Financial Liabilities		
Borrowings	200.3	214.8
Lease liabilities	1.0	1.0
Provisions	13.6	11.9
Deferred tax liabilities (net)	38.4	34.0
Other non-current liabilities	0.0	0.0
Current Liabilities	**573.2**	**494.6**
Financial Liabilities		
Borrowings	154.1	127.9
Trade payables	336.7	300.1
Other financial liabilities	52.3	46.6
Other current liabilities	17.5	12.6
Provisions	3.8	4.0
Current tax liabilities (net)	8.8	3.5
Total Equity & Liabilities	**1,994.1**	**1,837.8**

Consolidated Cash Flow

Particulars (₹ crore)	Sept-26	Sept-25
Net Profit Before Tax	**115.3**	**81.9**
Adjustments for: Non -Cash Items / Other Investment or Financial Items	30.1	28.5
Operating profit before working capital changes	**145.4**	**110.4**
Changes in working capital	(53.6)	(68.4)
Cash generated from Operations	**91.8**	**42.1**
Direct taxes paid (net of refund)	(19.2)	(12.4)
Net Cash from Operating Activities	**72.6**	**29.7**
Net Cash from Investing Activities	**(64.4)**	**(35.5)**
Net Cash from Financing Activities	**3.1**	**(9.2)**
Net Increase/ (Decrease) in Cash and Cash equivalents	**11.2**	**(15.0)**
Add: Cash & Cash equivalents at the beginning of the period	3.7	15.5
Cash & Cash equivalents at the end of the period	**14.9**	**0.5**

Key Strengths



Building on Core Strengths, Unlocking Future Growth

R&D Centric Organization

Comprehensive Business Model

Experienced Promoters and Board of Directors



Relentless Expansion of Manufacturing Capabilities: Fuel for Sustained Growth

Consistent Financial Performance

Relentless Expansion of Manufacturing Capabilities: Fuel for Sustained Growth (1/3)

Our manufacturing Capabilities

Baddi Plant

Building blocks for growth

2006 onwards

- Tablets
- Capsules
- Ointments
- Liquid Orals
- Dry Powder Injectables
- Dry Syrups

Dehradun & Taloja Plant

Expansion through Inorganic Acquisition

2024

- Tablets
- Capsules
- APIs

Acquired Sharon Bio Medicine Ltd on 30th June 2023

Jammu Plant

Expansion through New Greenfield Project

2025 onwards

- Tablets
- Capsules
- Dry Powder Injectables
- Dry Syrups
- BFS* (Large and Small Volume Parenterals and Respules)

Jammu Plant was commercialized in January 2025

**BFS: Blow Fill Seal*

Capacity Expansion in Jammu (2/3)

₹ 480+ crore

Total Capital Investment


Eligible for following benefits via Central Government's 'New Central Sector Scheme

GST-linked incentive totaling to 300% of investment made in eligible plant and machinery available for 10 years

Capital Interest Subvention of 6% per annum on loan against eligible capex

4 Independent Blocks

- Cephalosporin
- Penem
- Penicillin
- General











Growth led by Capacity Expansion (3/3)

Baddi Plant




- Expect current capacity to suffice the ongoing demand and increase the overall capacity utilization in upcoming years

Dehradun & Taloja Plant



- Sharon's manufacturing units are nearing optimal utilization, reflecting strong demand and efficient operations
- Aim to create long term synergy with additional product offerings in Formulation & API

Kathua, Jammu Plant



- Jammu facility has completed its first full year and is ramping up well, with multiple marquee client audits successfully completed

Comprehensive Business Model

CDMO Services and Products

- Preferred partner for companies seeking to efficiently deliver high-quality, affordable medicines to market.
- Consistently deliver high-quality solutions at scale, while maintaining the flexibility to tailor offerings to the distinct requirements of each partner
- Wide range of dosage forms, including oral solids, oral liquids, dry syrups, dry powder injectables, parenteral and ointments

4,200 +
Products

350 +
CDMO Customers

Branded Generics

- Company's domestic and international branded generics business has a broad reach, enabling it to address a wide spectrum of healthcare needs by effectively delivering high-quality formulations across the world

2,50,000 +
Touchpoints in India

60 +
Exported Countries



R&D Focused Organisation

60+
Scientist & Engineers

R&D Laboratory
Baddi, Himachal Pradesh

Robust Research and Development

- Dedicated R&D facility and pilot equipment located in Baddi, Himachal Pradesh, recognized by the DSIR for its in-house R&D work
- State-of-the-art facility equipped with a comprehensive suite of necessary tools for developing solid oral and liquid dosage forms, including RMG/FBP, compression machines, and auto coaters
- Analytical lab is equipped with advanced instruments such as HPLC, UV dissolution apparatuses, Karl Fischer moisture analyzers, sonicators, disintegration testers, thermal stability units, and fume hoods
- Developed Products in Category of Immediate Release, Super Bioavailability Capsules, Nano Size Formulation for Increased Bioavailability, Modified and Sustained Releases and Tablets in Capsules







Experienced Promoters and Board of Directors



Mr. Manoj Kumar Lohariwala
Chairman and Whole-Time Director



Mr. Vinay Lohariwala
Managing Director



Mr. Jayant Vasudeo Rao
Whole-Time Director



Mr. Archit Aggarwal
Non-Executive Non-Independent Director



Mr. Sudhir Kumar Bassi
Non-Executive Independent Director



Ms. Priyanka Dixit Sibal
Non-Executive Independent Director




Mr. Mahendar Korthiwada
Non-Executive Independent Director



Mr. Shirish Gundopant Belapure
Non-Executive Independent Director


Consistent Financial Performance

Revenue from Operations (₹ crore)




EBITDA (₹ crore)

12.4%	13.3%	15.4%	15.9%	15.4%




PAT (₹ crore)


8.0%	7.3%	8.7%	10.2%	8.8%	Margin




ROE/ROCE (%)*



Fixed Asset Turnover (FATR)*



Net Working Capital Days[1]



Note: Please refer the Prospectus for formulas
**ROCE/ROE and Fixed Asset Turnover ratio impacted by additional investment in Jammu plant and higher capital base due to IPO in Dec'23*
1 Net Working Capital impacted by increased inventory pertaining to Jammu plant

Historical Financial Performance



Consolidated Profit & Loss Statement

Profit and Loss (₹ crore)	FY26	FY25	FY24	FY23	FY22
Revenue from Operations	1,630.0	1,243.7	1,081.3	926.4	800.5
Other Income	7.4	12.0	12.5	9.2	2.9
Total Revenue	**1,637.4**	**1,255.7**	**1,093.8**	**935.6**	**803.4**
Cost of Materials Consumed	1,052.8	814.1	728.3	691.6	617.9
Employee Cost	167.2	116.8	90.7	54.8	40.5
Other Expenses	167.1	126.6	107.8	66.4	46.1
EBITDA	**250.3**	**198.2**	**166.9**	**122.8**	**98.9**
EBITDA Margin (%)	**15.4%**	**15.9%**	**15.4%**	**13.3%**	**12.4%**
Depreciation	45.2	24.8	16.0	11.1	7.5
Finance Cost	16.9	2.4	21.5	20.0	5.7
Profit before Tax	**188.3**	**171.0**	**129.5**	**91.8**	**85.7**
Tax	45.1	42.8	35.2	23.8	21.8
Profit After Tax	**143.2**	**128.3**	**94.3**	**68.0**	**64.0**
PAT Margin (%)	**8.8%**	**10.3%**	**8.7%**	**7.3%**	**8.0%**
EPS (in ₹)	**25.02**	**22.41**	**18.66**	**14.16**	**13.32**

Consolidated Balance Sheet

Assets (₹ crore)	FY26	FY25	FY24	FY23	FY22
Non - Current Assets	**914.9**	**877.3**	**741.1**	**261.9**	**196.4**
Property, plant and equipment	779.7	766.9	291.6	150.1	156.6
Right of use assets	43.7	45.5	48.7	15.3	9.3
Capital work-in-progress	15.5	22.5	340.8	21.5	-
Goodwill	16.7	16.7	16.7	16.7	16.7
Other intangible assets	1.5	0.7	0.9	0.8	0.5
Financial Assets					
Loans	0.4	0.7	0.7	0.5	0.2
Other financial assets	41.6	8.3	2.6	0.6	0.8
Deferred tax assets (net)	1.9	12.2	20.0	0.1	0.2
Income tax assets (net)	0.0	0.2	0.0	0.7	4.0
Other non-current assets	14.0	3.5	19.2	55.6	8.1
Current Assets	**923.0**	**703.1**	**579.8**	**442.5**	**379.1**
Inventories	283.3	208.0	144.0	117.3	128.4
Financial Assets					
Investments	41.3	-	-	-	-
Trade receivables	437.3	331.6	288.5	265.2	212.7
Cash and cash equivalents	3.2	15.5	11.7	3.5	0.2
Other bank balances	0.7	52.6	75.0	15.4	2.3
Loans	0.4	0.7	0.4	1.0	0.3
Other financial assets	86.9	32.1	7.6	7.2	4.3
Other current assets	69.9	55.1	52.4	32.9	30.9
Assets held for sale	0.0	7.4	0.0	-	-
Total Assets	**1,837.8**	**1,580.4**	**1,320.9**	**704.4**	**575.5**
Return on Net Worth	**13.24%**	**14.44%**	**12.42%**	**24.58%**	**30.66%**

Equity & Liabilities (₹ crore)	FY26	FY25	FY24	FY23	FY22
Total Equity	**1,081.5**	**959.4**	**830.9**	**276.5**	**208.6**
Share Capital	57.2	57.2	57.2	48.0	12.0
Other Equity	1024.3	902.2	773.7	228.5	196.6
Non-Current Liabilities	**261.7**	**268.0**	**224.5**	**150.4**	**72.4**
Financial Liabilities					
Borrowings	214.8	243.5	208.2	134.2	67.4
Lease liabilities	1.0	1.3	2.3	1.4	0.6
Other financial liabilities	-	-	-	7.9	-
Provisions	11.9	9.9	9.1	2.9	2.3
Deferred tax liabilities (net)	34.0	13.2	4.8	3.9	2.1
Other non-current liabilities		-	-	0.1	0.1
Current Liabilities	**494.6**	**352.9**	**265.5**	**277.6**	**294.5**
Financial Liabilities					
Borrowings	127.9	92.5	33.6	101.0	130.8
Lease liabilities	0.0	0.7	1.0	0.4	0.4
Trade payables	300.1	201.8	179.7	158.5	144.8
Other financial liabilities	46.6	31.8	29.6	11.5	9.3
Other current liabilities	12.6	17.9	17.7	5.6	7.8
Provisions	4.0	4.2	3.1	0.6	0.4
Current tax liabilities (net)	3.5	4.0	0.9	-	1.0
Total Equity & Liabilities	**1,837.8**	**1,580.4**	**1,320.9**	**704.4**	**575.5**
Debt/Equity Ratio	**0.32**	**0.35**	**0.29**	**0.85**	**0.95**

Consolidated Cash Flow

Particulars (₹ crore)	FY26	FY25	FY24	FY23	FY22
Net Profit Before Tax	**188.3**	**171.0**	**129.5**	**91.8**	**85.7**
Adjustments for: Non -Cash Items / Other Investment or Financial Items	**57.8**	**27.3**	37.2	25.9	15.3
Operating profit before working capital changes	**246.1**	**198.3**	**166.7**	**117.7**	**101.0**
Changes in working capital	(104.6)	(110.7)	7.3	(31.1)	(21.3)
Cash generated from Operations	**141.5**	**87.6**	**174.0**	**86.7**	**79.7**
Direct taxes paid (net of refund)	(26.3)	(23.7)	(27.7)	(19.5)	20.8
Net Cash from Operating Activities	**115.2**	**63.8**	**146.4**	**67.1**	**58.9**
Net Cash from Investing Activities	**(105.8)**	**(151.6)**	**(499.0)**	**(90.8)**	**(188.3)**
Net Cash from Financing Activities	**(21.7)**	**91.5**	**360.7**	**27.1**	**124.8**
Net Increase/ (Decrease) in Cash and Cash equivalents	**(12.3)**	**3.8**	**8.2**	**3.4**	**(4.8)**
Add: Cash & Cash equivalents at the beginning of the year	15.5	11.7	3.5	0.2	5.0
Cash & Cash equivalents at the end of the year	**3.2**	**15.5**	**11.7**	**3.5**	**0.2**



Thank You!

Innova Captab Limited :

Innova Captab Ltd.
CIN – L24246MH2005PLC150371
Mr. Lokesh Bhasin
Email – investors@innovacaptab.com
www.innovacaptab.com

Investor Relations Advisor :

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Ms. Shaily Patwa / Mr. Shrikant Sangani
Email – shaily.p@sgapl.net / shrikant.sangani@sgapl.net
Mobile No – 9819494608 / 9619595686
www.sgapl.net